Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1900272 | 0.99 | LMNA (0.48) | LMNACHRM4SMYD3EPHX1PIM1 | |
| SCHEMBL1898830 | 0.82 | LMNA (0.48) | LMNACHRM4PIM1CHRM2CHRM1 | |
| SCHEMBL2554545 | 0.82 | LMNA (0.48) | LMNACHRM4PIM1CHRM2CHRM1 | |
| SCHEMBL1898794 | 0.80 | LMNA (0.51) | LMNACHRM4CHRM2CHRM1GAA | |
| SCHEMBL1899913 | 0.74 | LMNA (0.53) | LMNAEPHX1GAAPOLBALDH1A1 | |
| SCHEMBL2686289 | 0.73 | CHRM4 (0.54) | LMNACHRM4CHRM2CHRM1KDM4E | |
| SCHEMBL3455901 | 0.72 | LMNA (0.67) | LMNACHRM4POLBHSD11B1KDM4E | |
| SCHEMBL8551225 | 0.71 | LMNA (0.39) | LMNACHRM4CHRM2CHRM1GAA | |
| SCHEMBL8551232 | 0.71 | LMNA (0.39) | LMNACHRM4CHRM2CHRM1GAA | |
| Hydrochloric Acid SCHEMBL8627559 | 0.70 | LMNA (0.43) | LMNACHRM4CHRM2CHRM1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496230-B1 | IRE-1 ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-20180072745-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-9856266-B2 | IRE-1alpha inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-15 | — | — | US | disclosed |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-15 | — | — | US | disclosed |
| US-9493435-B2 | IRE-1α inhibitors | MANNKING CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493435-B2 | IRE-1α inhibitors | MANNKING CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2496230-A1 | IRE-1 ALPHA INHIBITORS | MannKind Corporation (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056744-A1 | IRE-1 α INHIBITORS | MANNKIND CORPORATION (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056744-A1 | IRE-1 α INHIBITORS | MANNKIND CORPORATION (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072745-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | LMNA 2347/4885CHRM4 4883/4885SMYD3 4138/4885 |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | LMNA 2347/4885CHRM4 4883/4885SMYD3 4138/4885 |
| US-20170166576-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | LMNA 2347/4885CHRM4 4883/4885SMYD3 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.